Literature DB >> 24849194

Pregabalin's abuse potential: a mini review focusing on the pharmacological profile.

Georgios Papazisis, Dimitrios Tzachanis.   

Abstract

Pregabalin, an analogue of the gamma-aminobutyric acid mammalian neurotransmitter and its structurally related compound gabapentin are known as α2δ ligands. They might act as inhibitory modulators of neuronal excitability that reduce ectopic neuronal activation of hyperexcited neurons while normal activation remains unchanged. However, the interaction with Ca²⁺ channel α2δ subunit is not sufficient to account for the broad clinical spectrum of pregabalin effects including the abuse potential. Pregabalin is approved for the treatment of partial epilepsy; generalized anxiety disorder; peripheral and central neuropathic pain and fibromyalgia. Its prescribing is rapidly increasing and total sales of the drug worldwide reached 4.6 billion US$ in 2012. Since entering widespread clinical use, reports of pregabalin abuse appeared more often, usually involving individuals with a history of abuse of other medications. The purpose of this mini review is to present available published data signaling pregabalin's abuse liability reflecting on the pharmacological characteristics that might enable this agent to trigger addictive behaviors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24849194     DOI: 10.5414/CP202118

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  13 in total

Review 1.  Abuse Potential of Pregabalin: A Systematic Review.

Authors:  Ole Schjerning; Mary Rosenzweig; Anton Pottegård; Per Damkier; Jimmi Nielsen
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

Review 2.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 3.  Anxiety in Patients with Schizophrenia: Epidemiology and Management.

Authors:  Henk Temmingh; Dan J Stein
Journal:  CNS Drugs       Date:  2015       Impact factor: 5.749

4.  Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition.

Authors:  Rob Hill; William L Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2018-05-07       Impact factor: 8.739

5.  Risk to heroin users of polydrug use of pregabalin or gabapentin.

Authors:  Abigail Lyndon; Suzanne Audrey; Claudia Wells; Erica S Burnell; Suzanne Ingle; Rob Hill; Matthew Hickman; Graeme Henderson
Journal:  Addiction       Date:  2017-05-15       Impact factor: 6.526

Review 6.  Restless legs syndrome-current therapies and management of augmentation.

Authors:  Claudia Trenkwalder; Juliane Winkelmann; Yuichi Inoue; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2015-07-28       Impact factor: 42.937

Review 7.  Gabapentin misuse, abuse and diversion: a systematic review.

Authors:  Rachel V Smith; Jennifer R Havens; Sharon L Walsh
Journal:  Addiction       Date:  2016-03-18       Impact factor: 6.526

8.  Inappropriate Preoperative Gabapentinoid Use Among Patients With Carpal Tunnel Syndrome.

Authors:  Jessica I Billig; Erika D Sears; Vidhya Gunaseelan; Katherine B Santosa; Theodore J Iwashyna; Michael J Englesbe; Chad M Brummett; Jennifer F Waljee
Journal:  J Hand Surg Am       Date:  2020-05-30       Impact factor: 2.230

9.  A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.

Authors:  Stefania Chiappini; Fabrizio Schifano
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

10.  Assessment of the Safety Signal for the Abuse Potential of Pregabalin and Gabapentin Using the FAERS Database and Big Data Search Analytics.

Authors:  Georgios Papazisis; Dimitrios Spachos; Spyridon Siafis; Niki Pandria; Eleni Deligianni; Ioannis Tsakiridis; Antonios Goulas
Journal:  Front Psychiatry       Date:  2021-05-20       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.